PRAX
Praxis Precision Medicines, Inc.274.51
-1.89-0.68%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Standard review times ulixa payer dynamics
Q&A clarified Praxis chose standard review for ulixacaltamide's NDA to optimize launch timing amid payer dynamics and IRA impacts on Medicare Part D, securing priority review for relutrigine's smaller rare-disease package instead. Commercial prep ramps with key hires, inventory builds, and heavier allocation to ulixa's $10B ET market over relutrigine's DEEs, plus 15 AAN presentations detailing Essential3 responder data and alternative titration proposals sans extra trials. Vormatrigine's POWER3 monotherapy targets untapped 70-80% early-line focal epilepsy patients; RADIANT OLE hints at background med cuts without seizure rebound. EMERALD enrollment surges with diverse DEEs. No ADCOM signals. Management dodged ex-US talk, laser-focused on U.S. launches. Q&A adds execution color, not drama.
Key Stats
Market Cap
6.86BP/E (TTM)
-Basic EPS (TTM)
-12.96Dividend Yield
0%Recent Filings
8-K
NDAs submitted for two drugs
Praxis Precision Medicines submitted NDAs for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A DEEs on February 19, 2026, after positive Phase 3 data and FDA Breakthrough designations. Pre-launch ramps up across both, while topline results for vormatrigine and elsunersen loom in H1 2026. Cash hit $926M at year-end 2025, bolstered by $621M from January offering—funds into 2028. Leadership strengthened.
10-K
FY2025 10-K filing
Praxis Precision Medicines filed its 10-K for FY2025 ended December 31, 2025, with 27.9 million shares outstanding as of February 2026. No financial statements, revenue, profitability, or quarterly results appear in the provided filing. Exhibits detail executive employment agreements with severance terms, performance-based RSUs tied to milestones or sale events, and real estate arrangements including a sublease extension to February 2026 at $112K monthly base rent and a new license for 26,104 sq ft starting March 2026 at $57/sq ft annually. Cash position not disclosed. Clinical trial delays threaten momentum.
8-K
Exec appointments strengthen leadership
Praxis Precision Medicines appointed Megan Sniecinski as COO effective January 1, 2026, boosting her prior Chief Business Officer role with a $626,000 base salary and 50% target bonus. The board elected independent directors Jeffrey B. Kindler and Stuart A. Arbuckle as Class II members effective January 8. Leadership bolsters operations. No related transactions disclosed.
8-K
Priced $621M stock offering
Praxis Precision Medicines priced a $621.2 million common stock offering at $260 per share on January 6, 2026, with 2,543,800 shares sold after underwriters fully exercised their 331,800-share option. Closing is set for January 8, subject to customary conditions. Proceeds will fund commercialization prep, R&D, and operations into 2028 alongside existing cash. Cash burn assumptions could prove wrong.
8-K
Praxis holds $925M cash
Praxis Precision Medicines reported approximately $925 million in cash, cash equivalents, and marketable securities as of December 31, 2025, based on preliminary unaudited estimates. This strong liquidity position underscores financial stability amid pipeline development. Figures await audit. Risks include closing adjustments.
AEON
AEON Biopharma, Inc.
1.03+0.17
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
AXSM
Axsome Therapeutics, Inc.
146.87+0.63
BTAI
BioXcel Therapeutics, Inc.
1.88+0.01
HRMY
Harmony Biosciences Holdings, I
38.83-0.09
IONS
Ionis Pharmaceuticals, Inc.
78.37-1.39
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
RPTX
Repare Therapeutics Inc.
2.23+0.03